1520277181
Treating Together

Advertise on podcast: Treating Together

This podcast has
101 episodes
Language
English
Explicit
No
Date created
2020/06/24
Latest episode
2026/11/10
Average duration
17 min.
Release period
13 days

Description

Targeted Oncology brings you Treating Together, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.

Unlock Treating Together podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Treating Together podcast


The Patients Missing From Breast Cancer Data
2026/11/10
A single label can hide a lot. In this episode of Targeted Talks, two researchers look at what broad racial and ethnic categories obscure in breast cancer research, and what it would take to see more clearly. First, Scarlett Lin Gomez, professor of epidemiology and biostatistics at the University of California, San Francisco, discusses a large study of survival among Asian American women with breast cancer. Her team confirmed that most of the larger Asian American ethnic groups had better survival than non-Hispanic white women. They then adjusted for clinical, treatment, lifestyle, and neighborhood factors, and the advantage persisted. She explains why the group is far from uniform, with some 30 ethnic groups and about 100 languages and dialects, and why patterns by birthplace differed from group to group. The results are not ready to change practice guidelines, she says, but clinicians should know the variation exists. Next, Evanthia Roussos Torres, MD, PhD, assistant professor of medicine in the Division of Oncology at the University of Southern California, explains why Hispanic patients are rarely enrolled in breast cancer trials, and what that leaves unanswered. She describes how researchers can define the group beyond self-reported ethnicity, using ancestry genome arrays alongside surveys of where patients and their families come from. She also outlines her lab’s work on suppressive myeloid cells in breast tumors, why breast cancer has responded only modestly to checkpoint inhibitors, and her biggest open question: how much of that suppression must be overcome. Whether ancestry shapes immune response is still unknown, she stresses, and answering it will take time and more patients taking part in research. Both guests make the same point from different angles: better questions require better data, and better data requires the patients to be seen. Listen for what each researcher would change next.
Beyond the Scan: Predicting Immunotherapy Response With ctDNA in NSCLC
2026/11/03
Valsamo “Elsa” Anagnostou, MD, PhD, of Johns Hopkins University School of Medicine, joins Targeted Talks to discuss a study on landmark circulating tumor DNA (ctDNA) molecular response in patients with metastatic non–small cell lung cancer (NSCLC) treated with immunotherapy. Radiographic imaging, the current gold standard, can be slow and imprecise at capturing immunotherapy response. Anagnostou explains why a rapid molecular readout is needed to tailor treatment. In the prospective study of 109 patients, undetectable ctDNA 3 to 9 weeks after starting anti–PD-(L)1 therapy, alone or in combination, signaled clinical benefit. Persistent ctDNA signaled molecular disease progression. A single on-treatment measurement predicted outcomes as well as the traditional 2-time point approach, which compares ctDNA at baseline with a later time point. That matters for patients who miss a baseline draw or have no detectable ctDNA at baseline. Clearing ctDNA even once in the window predicted outcome, regardless of variability in readouts within the window. Anagnostou also covers: What’s still needed: Evidence that adapting treatment to ctDNA improves survival. The BR.36 trial, which she chairs, tests this in metastatic NSCLC with high PD-L1 expression. All patients start pembrolizumab. At 6 weeks, patients with detectable ctDNA are randomized to continue pembrolizumab or intensify with chemotherapy. Challenges: Choosing assays that fit the clinical setting, and handling technical and biological noise. Some mutations detected in blood come from blood cells rather than the tumor. What clinicians can do now: Enroll patients in ctDNA-adaptive trials. Serial liquid biopsy is already common practice in oncogene-driven NSCLC, such as EGFR-mutant and ALK-rearranged disease. It is also used informally when imaging is unclear.
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
2026/10/20
On this episode of Targeted Talks, Lyudmila Bazhenova, MD, discusses the FDA’s expanded label approval of taletrectinib (Ibtrozi) for ROS1-positive non–small cell lung cancer (NSCLC). She explains that the approval is based on data already presented at the 2026 AACR Annual Meeting, which showed efficacy in both TKI-naive and TKI-pretreated patients with longer follow-up. In TKI-naive patients, pooled analysis showed an intracranial overall response rate of 76.5%, a median duration of response of 49.7 months, and a median progression-free survival of 46.1 months, with no new safety signals. Bazhenova also reviews 2 new subset analyses from the 2026 World Conference on Lung Cancer: efficacy was similar in patients with and without prior chemotherapy, and it did not differ by ROS1 fusion partner (CD74 vs non-CD74). She shares her approach to managing side effects, including monitoring liver function tests and proactively managing diarrhea, and discusses the ongoing adjuvant trial in resected early-stage ROS1-positive NSCLC.
Lung Cancer in Hispanic and Latinx Patients: Risk Factors, Biomarkers, and Clinical Trial Access
2026/10/13
In this episode of Targeted Talks, recorded for Hispanic Heritage Month, Narjust Florez, MD, of Dana-Farber Cancer Institute, explains what oncologists should know about lung cancer in Hispanic and Latinx patients, one of the fastest-growing patient populations in the United States. Florez describes how risk factors in this population often extend beyond tobacco, including radon exposure, occupational and indoor air pollution such as cooking fumes, and a history of tuberculosis. She discusses the higher frequency of adenocarcinoma and driver alterations, including EGFR, KRAS, and ALK, in the Hispanic and Latinx population, and why biomarker testing is essential for every patient with nonsquamous non–small cell lung cancer. She also explains why treating Hispanic and Latinx patients as a single risk group can obscure differences in ancestry, migration patterns, and health care experience. The conversation also covers barriers to clinical trial enrollment, including consent forms that aren’t translated, unconscious bias, and mistrust of the health care system, along with practical steps clinicians can take, such as “going beyond the no” when a patient declines a trial. Florez closes by describing the EQUAL study which is evaluating a blood test to help detect EGFR-mutated lung cancer earlier. Learn more about the EQUAL study: https://equalstudy.dana-farber.org/
Dr Jhaveri on the FDA Approval of Imlunestrant Plus Abemaciclib for ESR1-Mutated Breast Cancer
2026/10/06
Komal Jhaveri, MD, joins Targeted Talks to discuss the FDA approval of imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio) for patients with ESR1-mutated, estrogen receptor–positive, HER2-negative metastatic breast cancer. She explains the unmet need, noting that existing endocrine monotherapies leave many patients without a durable benefit. She then reviews the design of the phase 3 EMBER-3 trial (n = 874) and the updated analysis with 28.5 months of follow-up. In ESR1-mutated disease, progression-free survival with imlunestrant monotherapy was 5.5 vs 3.8 months (HR, 0.62), with a numerical overall survival gain of 34.5 vs 23 months. The combination showed a benefit over imlunestrant alone, including in patients previously treated with a CDK4/6 inhibitor. Dr Jhaveri also covers the safety profile, the broader NCCN-endorsed population, potential use in the first-line setting for patients with brain metastases or a known baseline ESR1 mutation, and the ongoing phase 3 EMBER-4 adjuvant trial.
Dr Herzberg on the Expanding Toolkit in KRAS-Mutant Non–Small Cell Lung Cancer
2026/09/29
In this episode of Targeted Talks, Benjamin Herzberg, MD, discusses the evolving treatment landscape for KRAS-mutant non–small cell lung cancer (NSCLC). He explains why KRAS matters to all oncologists, since these mutations drive roughly 30% of NSCLC cases, and reviews why chemoimmunotherapy remains the first-line standard of care for now. He also covers how central nervous system metastases affect treatment planning and why close collaboration with pathology and upfront biomarker testing are essential. Herzberg then turns to the pan-RAS inhibitor daraxonrasib (Rasonque), recently approved in pancreatic cancer, and explains why lung cancer clinicians should pay attention. He discusses its published lung cancer data, which show response rates and durability similar to those in pancreatic cancer, as well as the ongoing phase 3 trial vs docetaxel. He also discusses zoldonrasib, a G12D-specific inhibitor with a favorable tolerability profile, and the idea of a "RAS toolkit" of pan-RAS and allele-specific agents. He closes with the biggest unmet needs, including driver-negative disease and resistance to targeted therapy, and what excites him most: molecular glues and other novel drug modalities, including MTAP/PRMT5 inhibitors. 00:00 Introduction to KRAS-Mutant Lung Cancer00:40 Prevalence and Variants of KRAS Mutations01:41 First-Line Chemoimmunotherapy for KRAS NSCLC03:15 Managing CNS Metastases in Lung Cancer05:11 Upfront Biomarker Testing and Collaboration08:05 Adagrasib's Role in KRAS-Mutant Lung Cancer10:22 Unmet Needs and Resistance Mechanisms12:31 Future of RAS Inhibitors and the RAS Toolkit
ASTRO 2026 Preview: Dr Raj Singh on De-Escalation, Brain Metastases, and What's Next in Radiation Oncology
2026/09/24
Ahead of the 2026 ASTRO Annual Meeting, Dr Raj Singh of Baptist Health joins the podcast to break down the studies he's watching most closely. The conversation opens with a pooled analysis of 3 phase 2 trials using FMISO PET imaging to identify hypoxic tumor regions and select patients with HPV-positive head and neck cancer who may safely de-escalate radiation dose, and Singh discusses what it would take to move this biomarker-driven approach beyond a single high-volume academic center. He then turns to updated C-POST data on the timing of cemiplimab initiation after radiotherapy in high-risk cutaneous squamous cell carcinoma, and to Alliance A071801, a phase 3 trial comparing single-fraction vs fractionated stereotactic radiosurgery to the resection cavity after brain metastasis surgery, including why patient-reported cognitive and emotional well-being end points matter alongside recurrence-free survival. The discussion moves to two practice-shaping trials in small cell lung cancer: MAVERICK, which found no overall survival benefit for prophylactic cranial irradiation over MRI surveillance alone in limited-stage disease, and NRG CC009, comparing radiosurgery with hippocampal-avoidance whole brain radiotherapy plus memantine for patients with limited brain metastatic disease. Singh explains how these results may accelerate an already-underway shift away from whole brain radiotherapy. The episode closes with a look at TRIDENT, a tumor-treating fields trial in newly diagnosed glioblastoma that missed its primary end point, and what subgroup data might still reveal—plus Singh's broader take on radiation oncology's shift toward patient-reported, quality-of-life-focused outcomes.
Bringing CAR T and Bispecifics to the Community
2026/09/22
Andrew Dalovisio, MD, a hematologist/oncologist at Mary Bird Perkins Cancer Center in Baton Rouge, Louisiana, discusses how his community cancer center built a CAR T and bispecific antibody program from the ground up. He walks through the toxicities associated with these T-cell–engaging therapies, including cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), and explains how prophylactic measures and a robust home-monitoring program have made outpatient management feasible. Dalovisio also addresses disparities in access, including insurance coverage gaps and the caregiver burden patients face, updates on REMS program changes affecting travel restrictions, and long-term complications like cytopenias and neurotoxicity that require coordination with academic centers. He closes with advice for oncologists on counseling patients as these therapies move toward earlier lines of treatment.
Rethinking HER2: A Pan-Cancer Look at IHC, ERBB2, and Tumor-Agnostic Testing
2026/09/15
HER2 has long been synonymous with breast cancer, but a growing body of evidence shows it's expressed, at some level, across nearly every solid tumor type. In this episode of Targeted Talks, host Sabrina Serani sits down with Dr Aditya Shreenivas (City of Hope National Medical Center) and Dr Razelle Kurzrock (Medical College of Wisconsin Cancer Center) to unpack their new real-world analysis, published in ESMO Open, using data made available by Caris Life Sciences, examining HER2 immunohistochemistry (IHC) expression and ERBB2 alterations across more than 200,000 tumors. The conversation traces how HER2 evolved from a breast cancer biomarker to a tumor-agnostic target, following the accelerated approval of fam-trastuzumab deruxtecan (T-DXd; Enhertu) for HER2 IHC 3+ solid tumors. Drs Shreenivas and Kurzrock walk through the study's key findings: how ERBB2 amplification and mutation status each relate to HER2 IHC expression, why that relationship is more complex—and more clinically important—for mutations than for amplifications, and what it means when the biomarkers disagree. They also dig into overall survival data showing that the prognostic benefit of high HER2 expression is largely concentrated in breast and gastric cancers, where HER2-targeted therapies are already standard of care, vs rarer tumor types like salivary gland and endometrial cancer, where the picture looks different. Listeners will come away with a clearer sense of why HER2 should be treated as a continuous variable rather than a binary positive/negative result, why routine HER2 IHC testing matters for every patient with unresectable or metastatic disease, and where the open questions remain, including discordant cases where amplification and IHC don't line up. A must-listen for oncologists, pathologists, and researchers working across breast, GI, gynecologic, and rare solid tumors who want a real-world, pan-cancer view of the evolving HER2 landscape.
Radiation Oncology's Financial Squeeze with Dr Ryan Funk
2026/09/08
In this episode of Targeted Talks, Sabrina Serani speaks with Dr Ryan Funk, chief radiation oncology officer at The US Oncology Network and a radiation oncologist with Minnesota Oncology, about the financial pressures reshaping radiation oncology in 2026. While CMS's overhaul of treatment delivery codes into complexity-based tiers has drawn attention, Dr. Funk argues that commercial payer contracts—not Medicare—are the bigger driver of instability, since commercial reimbursement typically funds the margin practices need to reinvest in costly, aging equipment. Dr Funk discusses how practices are responding: tightening collections on contracted payments, delaying staffing cuts, and increasingly facing hard choices about whether to replace linear accelerators at all. He warns that the most visible effect won't be lower-quality care at existing centers, but outright closures, especially among freestanding and rural facilities, which have already seen disproportionate losses over the past decade. Since about half of all patients with cancer require radiation, and access is especially critical for patients traveling daily for treatment, he stresses that this is a multidisciplinary concern, not just a radiation oncology one. The conversation also covers the role of patient advocacy groups, employers, and professional societies like ASTRO and ACRO in applying pressure at both the national and local contract levels, and Dr Funk's advice for physicians to engage more directly with the business side of their practices.
Gynecologic Cancer Trends, Testing, and Treatment Advances Explained
2026/09/01
Gynecologic cancer incidence is moving in 3 different directions at once, and clinicians outside gynecologic oncology are often the first to see the warning signs. Ovarian cancer incidence is falling as genetic testing and risk-reducing surgery catch more high-risk women before diagnosis, even as its prevalence climbs because patients are living longer on treatment. Cervical cancer incidence continues to decline thanks to Pap and HPV co-testing plus vaccination, though it has not been eliminated. Endometrial cancer is the outlier: incidence is rising, driven largely by aggressive, high-grade subtypes that disproportionately affect Black women.¹ In this episode of Targeted Talks, Sabrina Serani, managing editor of Targeted Oncology, spoke with Noelle Gillette Cloven, MD, a gynecologic oncologist at Texas Oncology's Fort Worth Cancer Center and executive chair of the GYN Research Committee at Sarah Cannon Research Institute, to discuss how these shifting patterns should inform testing, screening, and referral decisions in everyday practice. The conversation is timed to Gynecologic Cancer Awareness Month, observed each September to raise awareness of cervical, ovarian, uterine, vaginal, and vulvar cancers. A recurring theme was the distinction between germline and somatic testing in ovarian cancer. Germline testing, done via blood or cheek swab, identifies inherited mutations in genes such as BRCA1 and BRCA2, present in roughly 20% of ovarian cancers, and carries implications for the patient's relatives. Somatic testing of the tumor itself, including homologous recombination deficiency (HRD) status, is a separate question that determines which patients are likely to benefit from PARP inhibitor maintenance therapy after chemotherapy. Cloven emphasized that an adequate core biopsy, not a fine-needle aspiration, is essential to secure enough tissue for HRD testing and to distinguish high-grade from low-grade serous disease, since treatment approaches for the two differ substantially. Screening gaps surfaced repeatedly. Extended Pap and HPV testing intervals, while evidence-based, make it harder for patients to track when they are due, and Cloven pushed back on guidance to stop cervical cancer screening at 65, noting that more than a third of cervical cancer cases are diagnosed after that age. In endometrial cancer, postmenopausal bleeding is rarely missed, but irregular bleeding in women under 40 is often attributed to obesity or PCOS and treated with oral contraceptives without a biopsy, delaying diagnosis in a population where the disease is less common but not absent. Cloven also flagged a persistent misconception among patients and some clinicians: a Pap test screens only for cervical cancer, not for ovarian, endometrial, or vulvar disease, and a well-woman exam does not automatically include one. On the treatment horizon, Cloven pointed to antibody-drug conjugates producing response rates in platinum-resistant ovarian cancer that she described as the best she has seen in her career, immunotherapy's role in extending survival in metastatic cervical cancer, and early movement toward non-chemotherapy, receptor-targeted options for advanced endometrial cancer guided by molecular profiling. For clinicians outside gynecologic oncology, Cloven's practical takeaways were straightforward: take a thorough family history, since it is often the entry point to genetic testing; do not substitute imaging or a prescription for a pelvic exam when a patient has persistent symptoms; and consider a clinical trial referral at diagnosis rather than as a last resort, since it may offer earlier access to newer therapies. REFERENCE1. Gaber C, Meza R, Ruterbusch JJ, Cote ML. Endometrial cancer trends by race and histology in the USA: projecting the number of new cases from 2015 to 2040. J Racial Ethn Health Disparities. 2017;4:895-903. doi:10.1007/s40615-016-0292-2
AI in Oncology: Managing Information Overload for Trainees and Patients
2026/07/15
In part 2 of this conversation, oncologists discuss how they help both patients and trainees navigate an overwhelming volume of medical information. The speakers describe encouraging patients to consult reliable resources like NCCN's patient site rather than turning solely to AI chatbots, while also acknowledging patients will inevitably seek outside information and clarification from family. For fellows, the panel emphasizes using training time intentionally: reading about patients in depth before appointments, focusing on core algorithms during subspecialty rotations, and building relationships with mentors who can be lifelong resources. Dr Demel highlights curated tools like condensed literature summaries and topic-specific podcasts as more efficient than reading full journals, especially given the explosive growth in oncology trials and publications over the past two decades alongside rising retraction rates. Dr Mehta describes using voice-based AI during a daily commute to get updated on relevant papers, a habit some fellows have since adopted. The discussion turns to varying attitudes toward AI among colleagues, with speakers describing a spectrum from enthusiastic adopters to skeptics wary of hallucinations. Dr Ji stresses recognizing "good enough" knowledge limits, using AI to stay current on standard-of-care changes and practice-changing trials, while emphasizing that human collaboration and communication remain essential when navigating complex cases beyond one's expertise. The conversation closes with reflections on reading outside one's specialty to address patients' broader health needs, including medication interactions and comorbidities. Panelists describe current AI use as still in its "infancy," with promising applications emerging in patient monitoring, wearable data, and predictive analytics. Take-home messages include "cautious optimism" about AI's power and a prediction that oncologists who learn to use AI effectively will have a distinct advantage in the field's future.
Drowning in Data: How Oncologists Are Coping with Information Overload in the AI Era
2026/07/01
In this episode of Treating Together, host Dr Pallav Mehta sits down with Dr Kurt Demel and Dr Yan Ji, 2 community-based medical oncologists practicing in the Twin Cities, to tackle a problem every oncologist feels but few have named clearly: information overload. The conversation opens with a deceptively simple question: When does learning become overload? The group traces the line from the genuine joy of working in a constantly evolving field to the point where the sheer volume of trial data, survival end points, and subgroup analyses makes it hard to land on a clear recommendation for the patient in the room. Dr Ji offers a memorable framing for this: the "memory battery" that drains over the course of a clinic day, leaving even thorough research feeling unresolved when conflicting trials point in different directions. From there, the discussion moves into how oncologists actually cope by leaning on colleagues through email threads and group chats, the growing divide between generalist and subspecialist practice, and how increasingly informed patients (armed with their own ChatGPT printouts) are reshaping the visit itself. The back half of the episode digs into AI's expanding role in oncology: ambient note-taking, evidence-summarization tools like OpenEvidence, and AI-assisted clinical trial matching, alongside real concerns about hallucinated summaries, erosion of foundational clinical reasoning in trainees, and the risk of applying trial data to patients who don't resemble the trial population. The episode closes on a note of cautious optimism—AI as a tool to clear away noise, not a replacement for the clinical judgment and human connection that the panel agrees remains the real value an oncologist brings to a patient.
Navigating the 505(b)(2) Pathway: Operational, Clinical, and Economic Strategies for Oncology Practices
2026/06/17
In this episode, managing editor Sabrina Serani sits down with 3 experts at the intersection of oncology pharmacy, health informatics, and drug distribution to unpack the 505(b)(2) regulatory pathway and what it means for cancer centers navigating today's complex drug landscape. Guests: Jessica White, PharmD, Vice President, Specialty Programs & Portfolio Management at McKesson Derek Burns​, PharmD, Senior Director, MID Solutions at McKesson Nick Brady​, Director, Health Informatics at Central Arkansas Radiation Therapy Institute (CARTI)​ What We Cover:The 505(b)(2) Pathway Explained — Jessica breaks down how the 505(b)(2) new drug application differs from a traditional NDA, allowing drug developers to build on existing FDA-recognized data through bridging studies. The result: faster approvals, lower development costs, and drugs that improve on — rather than simply duplicate — what's already on the market. Why Oncology, Why Now — Nick explains how 505(b)(2) drugs address a critical pain point in oncology practice: supply disruption. When reference products go on allocation or become unavailable, these drugs provide a meaningful alternative — and in some cases, meaningful clinical improvements like reduced toxicity, modified dosage forms, or improved adherence. The Real Friction Points — Derek identifies where practices actually get stuck: not at the clinical level, but in operations. Launching without a brand name, missing J-codes, absent ASP data, and gaps in the CMS NDC crosswalk all create hesitation in revenue cycle teams. The underlying problem, he argues, is almost never resistance to innovation — it's undefined coverage, coding, and workflow clarity at launch. Who Needs to Be at the Table — Nick walks through Carti's internal adoption process, emphasizing that economic evaluation must run in parallel with patient impact assessment. A cross-functional team — pre-certification, pharmacy (both infusion and dispensing), billing and coding, and claims monitoring — needs to move together, with a single source of truth so that no one on the front lines is working from conflicting information. Practical Strategies for Adoption — The group converges on two key approaches: front-load organizational alignment before the first dose is given, and start narrow with a defined pilot population before any broad rollout. Derek and Jessica also stress the value of a designated practice champion who can coordinate across departments and pressure-test coverage and economics in advance. The Patient at the Center — When everything is working, patients experience seamless transitions between products, fewer delays, and — in some cases — therapies that are easier to tolerate and stay on. The panel emphasizes that a well-integrated 505(b)(2) strategy should be invisible to the patient while delivering real downstream clinical and economic benefit. Safety Considerations — Derek underscores that practices managing multiple agents within the same drug category face real risks around dispensing, billing, and administration if labeling and workflows aren't airtight. Jessica notes that the industry is correcting course, with more manufacturers now launching 505(b)(2) products with distinct brand names — reducing the risk of misidentification. Where the Pipeline Is Headed — Jessica closes with a look at the road ahead: more branded manufacturers entering the 505(b)(2) space, a growing pipeline from traditional generic manufacturers focused on oncology, and a strategic emphasis on supply redundancy and clinical improvements for older, well-established agents that have experienced drug shortages. Key Takeaways: Treat 505(b)(2) drugs as an operational, clinical, and financial tool, not just an economic play. Every oncology practice will likely carry multiple agents in the same category; managing that inventory safely is non-negotiable. If you've seen one 505(b)(2), you've seen one. Ask what's actually different, what the evidence supports, and how it fits your patients. "Not yet" is more accurate than "never": even practices not ready to adopt should be educating staff now.
ASCO 2026 Preview: Late-Breaking Abstracts Poised to Reshape the Treatment Landscape
2026/05/20
Ahead of the 2026 ASCO Annual Meeting, Sabrina Serani, managing editor of Targeted Oncology, previews the late-breaking abstracts most likely to influence clinical practice across breast, colorectal, prostate, and lung cancer, as well as in metastatic uveal melanoma, a disease that has gone without an effective systemic therapy for decades. From VIKTORIA-1 in PIK3CA-mutant metastatic breast cancer to BREAKWATER's first look at overall survival in BRAF V600E-mutant colorectal cancer, this episode breaks down the science, the clinical context, and the questions that full data will need to answer.

Podcast reviews

Read Treating Together podcast reviews


0 out of 5
0 reviews

Podcast sponsorship advertising

Start advertising on Treating Together relevant audience podcasts


What do you want to promote?